Common adverse effects include gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation), which typically improve over time
Even at the highest dose of 2.4 mg, where the risk appears greatest, most patients tolerate the medication without developing this side effect
The three substances proposed for exclusion: Semaglutide the active ingredient in Ozempic, Wegovy, and Rybelsus Tirzepatide the active ingredient in Mounjaro and Zepbound Liraglutide the active ingredient in Victoza and Saxenda The FDAs stated rationale: with FDA-approved branded products commercially available, there is no clinical need for 503B outsourcing facilities to compound these medications from bulk substances
Methods: 25 women with PCOS and obesity, aged 33.7 5.3 years (mean SD), were treated with once-weekly subcutaneous semaglutide 1.0 mg as an adjunct to metformin 2000 mg/day and lifestyle intervention for 16 weeks
Research Use Disclaimer This product is intended strictly for laboratory research and analytical purposes only
